SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IRIX

Iridex Corp (NASDAQ:IRIX)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$0.69-$0.01 (-1.44%)
 
Market cap
$12.1M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 16, 1996
Website
Market Cap$12.12M-22.2%
Revenue (ttm)$51.57M+3.7%
Net Income-$3.55M+34.9%
EPS-$0.20+38.2%
Shares Out17.56M
PE Ration/a
Forward PE34.50
Dividendn/a
Ex-Dividend Daten/a
Volume5,597
Open$0.72
Previous Close$0.70
Day's Range$0.69 - $0.72
52-Week Range$0.61 - $1.65
Beta0.65
AnalystsBuy
Price Target$2.75(+298.55%)
Earnings DateNov 17, 2026
-1.44% (1D)
No price history available.

About IRIX

IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.

Address
1212 Terra Bella Avenue, Mountain View, CA, 94043, US
Market Cap
12 million
Employees
93
Industrial Classification
Medical - Devices

Iridex Corp Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
61st Percentile Overall Score
IRIX InsiderScore:76 / 99

Iridex Corp scored higher than 61% of companies evaluated by InsiderBuying, and ranked 17th out of 45 stocks in the healthcare sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Iridex Corp bought $15.0K of stock across 5 purchases in the last 90 days, the largest of them $5.0K.

Stake Increase

The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$103.85K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Sound
From IRIX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.44%
5 Days
+0.00%
1 Month
-18.66%
6 Months
-33.01%
1 Year
-22.24%

$IRIX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IRIX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IRIX's directors and management

Net Shares Purchased by Insiders−60k−30k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IRIX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

IRIX Revenue by Segment or Geography

$12.57MTotal
Retina$6.49M51.61%
Cyclo G6$3.92M31.20%
Other$2.16M17.20%

As of: Q3 2026 (Jul 4, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New IRIX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IRIX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in IRIX

VTIVanguard Morningstar Total Stock Market ETF$253.17K
VXFVanguard Extended Market ETF$71.03K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from IRIX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
91.45
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
19
Sells
0
Buy Value
$103.85K
Distinct Buyers
2

Insider Score Trend Over Time

-10.0 since Sep 15
0255075100Sep 15 — Insider Score 84.0Sep 16 — Insider Score 82.9Sep 17 — Insider Score 82.0Sep 18 — Insider Score 81.8Sep 19 — Insider Score 81.7Sep 20 — Insider Score 81.7Sep 21 — Insider Score 81.6Sep 22 — Insider Score 81.0Sep 23 — Insider Score 80.2Sep 24 — Insider Score 79.3Sep 25 — Insider Score 86.8Sep 26 — Insider Score 86.7Sep 27 — Insider Score 86.8Sep 28 — Insider Score 86.7Sep 29 — Insider Score 86.2Sep 30 — Insider Score 85.9Oct 1 — Insider Score 85.6Oct 2 — Insider Score 42.0Oct 3 — Insider Score 85.2Oct 4 — Insider Score 85.3Oct 5 — Insider Score 85.4Oct 6 — Insider Score 85.0Oct 7 — Insider Score 85.0Oct 8 — Insider Score 84.7Oct 9 — Insider Score 84.5Oct 10 — Insider Score 84.2Oct 11 — Insider Score 84.7Oct 12 — Insider Score 84.7Oct 13 — Insider Score 84.6Oct 14 — Insider Score 84.1Oct 15 — Insider Score 84.0Oct 16 — Insider Score 83.8Oct 17 — Insider Score 83.6Oct 18 — Insider Score 83.8Oct 19 — Insider Score 83.9Oct 20 — Insider Score 83.7Oct 21 — Insider Score 83.7Oct 22 — Insider Score 83.7Oct 23 — Insider Score 83.5Oct 24 — Insider Score 83.7Oct 25 — Insider Score 83.5Oct 26 — Insider Score 83.3Oct 27 — Insider Score 83.5Oct 28 — Insider Score 83.1Oct 29 — Insider Score 82.6Oct 30 — Insider Score 81.5Oct 31 — Insider Score 81.3Nov 1 — Insider Score 81.3Nov 2 — Insider Score 81.3Nov 3 — Insider Score 80.3Nov 4 — Insider Score 79.7Nov 5 — Insider Score 78.9Nov 6 — Insider Score 77.7Nov 7 — Insider Score 77.3Nov 8 — Insider Score 78.2Nov 9 — Insider Score 78.2Nov 10 — Insider Score 76.3Nov 11 — Insider Score 75.6Nov 12 — Insider Score 75.3Nov 13 — Insider Score 73.9Sep 15Oct 14Nov 13

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.